Get the Stockscreener App
22.40
60,115%
22.36
Pre-market:
22.39
-0.010
-0.04%
Aktis Oncology Inc stock is traded at $22.40, with a volume of 2.98M.
It is up +60,115% in the last 24 hours and up +60,115% over the past month.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.
See More
Previous Close:
$0.0372
Open:
$27
24h Volume:
2.98M
Relative Volume:
0.13
Market Cap:
$5.75M
Revenue:
$29.71M
Net Income/Loss:
$-69.15M
P/E Ratio:
-23.09
EPS:
-0.97
Net Cash Flow:
$-52.28M
1W Performance:
+60,115%
1M Performance:
+60,115%
6M Performance:
+60,115%
1Y Performance:
+60,115%
1-Day Range:
$19.33
$29.16
1-Week Range:
$19.33
$29.16
52-Week Range:
$19.33
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Name
Aktis Oncology Inc
Sector
Industry
Phone
-
Address
-
Compare AKTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTS
Akoustis Technologies Inc
|
22.40 | 5.75M | 29.71M | -69.15M | -52.28M | -0.97 |
|
CSCO
Cisco Systems Inc
|
73.88 | 292.22B | 57.70B | 10.60B | 12.73B | 2.6521 |
|
MSI
Motorola Solutions Inc
|
383.14 | 63.61B | 11.31B | 2.12B | 2.41B | 12.46 |
|
NOK
Nokia Corp Adr
|
6.48 | 35.99B | 21.81B | 920.12M | 1.46B | 0.175 |
|
UI
Ubiquiti Inc
|
559.91 | 33.23B | 2.76B | 791.81M | 589.67M | 13.08 |
|
CIEN
Ciena Corp
|
230.56 | 31.72B | 4.77B | 123.34M | 665.28M | 0.8495 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-06-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-24-23 | Initiated | B. Riley Securities | Buy |
| Feb-02-21 | Reiterated | Craig Hallum | Buy |
| Jan-15-21 | Reiterated | Craig Hallum | Buy |
| Sep-18-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-10-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-13-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Dec-18-18 | Initiated | Craig Hallum | Buy |
| Nov-30-18 | Initiated | Lake Street | Buy |
| Jun-22-18 | Initiated | Loop Capital | Buy |
| Feb-09-18 | Initiated | Drexel Hamilton | Buy |
View All
Aktis Oncology Inc Stock (AKTS) Latest News
Modified Reorganization Plan Approved On Final Basis for Akoustis Technologies, Inc. - marketscreener.com
Akoustis Gets OK For Ch. 11 Liquidation Plan - Law360
Akoustis Technologies, Inc. (AKTS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Essential US space, defense brand liquidates in Chapter 11 bankruptcy - TheStreet
Akoustis Gets OK For Ch. 11 Liquidation Plan Disclosures - Law360
EBITDA per share of Akoustis Technologies, Inc. – LS:A2DTX6 - TradingView
EBIT per share of Akoustis Technologies, Inc. – LS:A2DTX6 - TradingView
Benjamin F. Edwards & Company Inc. Buys 16,750 Shares of Akoustis Technologies, Inc. (NASDAQ:AKTS) - 富途牛牛
CapEx per share of Akoustis Technologies, Inc. – OTC:AKTSQ - TradingView — Track All Markets
Joint Reorganization Plan and disclosure statement Filed by Akoustis Technologies, Inc. - MarketScreener
Akoustis Strikes Deal With Rival On Sale, Ch. 11 Claims - Law360
Akoustis' Appeal Of $39M IP Verdict Dropped After Bankruptcy - Law360
Akoustis Bows Out of $39M IP War, Drops Appeal Amid Bankruptcy Battle - USA Herald
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Massive Nasdaq Purge: 18 Companies Face Delisting, Including EV Maker Canoo - Stock Titan
Bankrupt US Tech Firm Akoustis Snapped Up by SpaceX in $30M Power Play - Orbital Today
SpaceX acquires satellite component manufacturer Akoustis out of bankruptcy - Washington Times
SpaceX Closes Rare Acquisition Of Component Manufacturer - Payload Space
Subsidiary of Elon Musk's SpaceX buys assets of Huntersville company - The Business Journals
Akoustis Gets OK For $30M Sale To SpaceX Subsidiary - Law360
Akoustis Says $39M Ch. 11 Sales Don't Include Trade Secrets - Law360
AKTSAKTIS ONCOLOGY INC Latest Stock News & Market Updates - Stock Titan
LanzaTech expands board, appoints new director - Investing.com
Akoustis Technologies Delays Quarterly Report Filing - TipRanks
Akoustis Gets OK On Motions Tied To Ch. 11 Sale 'Cleanse' - Law360
Akoustis Technologies, Inc. (AKTSQ) stock price, news, quote and history - Yahoo Finance UK
Akoustis Technologies, Inc. (AKTSQ) interactive stock chart - Yahoo Finance Australia
Akoustis Technologies, Inc. (AKTSQ) Stock Price, News, Quote & History - Yahoo! Finance Canada
What is the current Price Target and Forecast for Akoustis Technologies (AKTSQ) - Zacks Investment Research
Check out ATech (Parent) Resolution Corp's stock price (AKTSQ) in real time - CNBC
Case Summary: Akoustis Technologies Chapter 11 - Bondoro
Huntersville public company files for Chapter 11 bankruptcy, plans sale - The Business Journals
Akoustis Technologies Initiates Bankruptcy for Strategic Asset Sale - TipRanks
AKTS stock plunges to 52-week low, touches $0.04 - Investing.com
Zacks Industry Outlook Highlights RF Industries and Akoustis - Nasdaq
2 Radio Frequency Stocks to Watch in a Challenging Industry - Yahoo Finance
Akoustis ordered to pay over $50 million after lawsuit - Investing.com
Akoustis Technologies Inc. (AKTS) Quarterly 10-Q Report - qz.com
Akoustis Technologies stock hits 52-week low at $0.05 - Investing.com India
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - marketscreener.com
Akoustis Technologies secures Nasdaq listing extension - Investing.com
Akoustis Technologies faces Nasdaq delisting over equity deficit - Investing.com
Akoustis Technologies names new CEO and board member - Investing.com
AKTS stock plunges to 52-week low of $0.06 amid market challenges - Investing.com UK
Akoustis Technologies faces financial uncertainty after legal setbacks - Investing.com
Qorvo Wins $11.7 Million in Attorneys Fees in Akoustis IP Suit - Bloomberg Law News
Qorvo Gets Nearly $12M In Fees After $39M Trade Secrets Win - Law360
AKTS stock plunges to 52-week low of $0.07 amid market challenges - Investing.com UK
Akoustis Technologies faces Nasdaq delisting over price - Investing.com
Slammed 42% Akoustis Technologies, Inc. (NASDAQ:AKTS) Screens Well Here But There Might Be A Catch - simplywall.st
Akoustis Technologies Overhauls Leadership and Board - TipRanks
Aktis Oncology Inc Stock (AKTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.90%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):